Table 3 Population and Baseline Characteristics
|  | Current Standard of Care (N = 50) | Strict Glucose Control (N = 50) | P-Value |
|---|---|---|---|
Patient Demographics | |||
Age | 55.0 [50.0 to 59.0] | 54.0 [48.0 to 57.0] | 0.201 |
Race | Â | Â | 0.580 |
 White | 41 (82.0) | 41 (82.0) |  |
 African American | 4 (8.0) | 5 (10.0) |  |
 Asian | 1 (2.0) | 0 (0.0) |  |
 Other | 4 (8.0) | 4 (8.0) |  |
WHO BMI Classification | Â | Â | 0.415 |
 Underweight | 0 (0.0) | 0 (0.0) |  |
 Normal | 12 (24.5) | 10 (20.0) |  |
 Overweight | 18 (36.7) | 14 (28.0) |  |
Obese | 19 (38.8) | 26 (52.0) | Â |
 Female Sex | 14 (28.0) | 12 (24.0) | 0.648 |
Pre-Existing Conditions | |||
 Diabetes | 16 (32.0) | 13 (26.0) | 0.509 |
 CAD | 4 (8.0) | 4 (8.0) | 0.999 |
 MELD Score | 20.5 [15.0 to 23.0] | 19.5 [12.5 to 25.5] | 0.744 |
Cause of Liver Disease1 | |||
 Alagille’s Syndrome | 0 (0.0) | 2 (4.0) | 0.495 |
 Alpha-1 Antitrypsin Deficiency | 4 (8.0) | 0 (0.0) | 0.118 |
 Hepatocellular Carcinoma (non-Fibrolamellar) | 13 (26.0) | 19 (38.0) | 0.198 |
 Alcohol-related Cirrhosis | 18 (36.0) | 12 (24.0) | 0.190 |
 Cryptogenic Cirrhosis | 4 (8.0) | 5 (10.0) | 0.999 |
 Primary Biliary Cirrhosis | 2 (4.0) | 1 (2.0) | 0.999 |
 Secondary Biliary Cirrhosis | 1 (2.0) | 0 (0.0) | 0.999 |
 Cystic Fibrosis | 1 (2.0) | 0 (0.0) | 0.999 |
 Hemochromatosis | 1 (2.0) | 0 (0.0) | 0.999 |
 Hepatitis C, Chronic | 18 (36.0) | 18 (36.0) | 0.999 |
 Hepatitis, Chronic Active | 2 (4.0) | 3 (6.0) | 0.999 |
 Hepatic Failure (Idiopathic) | 1 (2.0) | 0 (0.0) | 0.999 |
 HCC | 1 (2.0) | 1 (2.0) | 0.999 |
 Hypertensive Nephrosclerosis | 1 (2.0) | 0 (0.0) | 0.999 |
 Polycystic Liver Disease | 1 (2.0) | 0 (0.0) | 0.999 |
 Non-Alcoholic Steatohepatitis | 2 (4.0) | 4 (8.0) | 0.678 |
 Primary Sclerosing Cholangitis | 5 (10.0) | 8 (16.0) | 0.554 |
 Unknown | 1 (2.0) | 1 (2.0) | 0.999 |
 Wilson’s Disease | 0 (0.0) | 1 (2.0) | 0.999 |